A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Trial Parameters
Brief Summary
The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).
Eligibility Criteria
Inclusion Criteria: * Participant must be between 55 to 80 years of age (inclusive), at the time of signing the informed consent form. * Body mass index (BMI) of 19 to 34 kg/m2 (inclusive). * Must agree to use reliable contraception for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding. * The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening. * Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator. * For study eye, Normal Luminance BCVA of 55 letters or worse using the ETDRS charts (20/80 or worse) for Part 1a participants or 24 letters or better (approximately 20/320 Snellen equivalent) for Part 1b and Part 2 participants. * Fellow eye Normal Luminance BCVA of 5 letters or better using ETDRS charts (20/800 or better) for Part